FDA approves pediatric MS treatment and oncology drugs advance while safety concerns emerge around cancer screening tests and weight-loss drug interactions.

FDA grants approval for ocrelizumab to treat relapsing-remitting multiple sclerosis in children aged 10 and older, expanding treatment options for pediatric MS patients.

Oncologic Drugs Advisory Committee backs prostate cancer drug but rejects novel breast cancer regimen, underscoring ongoing challenges in establishing clinical meaningfulness standards for cancer treatments.

Datopotamab deruxtecan (Dato-DXd) demonstrates improved quality of life and physical functioning compared to chemotherapy in first-line triple-negative breast cancer treatment, strengthening its clinical case.

False-positive results from multi-target stool DNA cancer screening tests are associated with higher detection rates of noncolorectal aerodigestive cancers, suggesting additional workup protocols may be necessary.

Ultrafine water cluster technology shows promise in significantly reducing post-laser treatment erythema, offering a novel approach to managing laser-associated skin complications.

Research highlights evidence that Borrelia burgdorferi bacteria can cross the placenta, suggesting congenital Lyme disease may be associated with adverse pregnancy outcomes requiring further investigation.

Acid-blocking medications combined with weight-loss drugs significantly increase risk for multiple gastrointestinal conditions, raising concerns about concurrent use of these medications.

A 3-year study finds high-risk mental health patients in emergency departments remain inadequately monitored, though conditions have notably improved since 2023.